Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 PROTAC-Mediated Degradation of KRAS Protein for Anticancer Therapeutics.

Literature DB >> 31938454

PROTAC-Mediated Degradation of KRAS Protein for Anticancer Therapeutics.

Robert B Kargbo¹.

Abstract

Entities: Gene

Year: 2019 PMID： 31938454 PMCID： PMC6956371 DOI： 10.1021/acsmedchemlett.9b00584

Source DB: PubMed Journal: ACS Med Chem Lett ISSN： 1948-5875 Impact factor: 4.345

× No keyword cloud information.

4 in total

Review 1. The Role of KRAS in Endometrial Cancer: A Mini-Review.

Authors: Michail Sideris; Elif Iliria Emin; Ziena Abdullah; John Hanrahan; Konstantina Maria Stefatou; Vasileios Sevas; Ece Emin; Tony Hollingworth; Funlayo Odejinmi; Savvas Papagrigoriadis; Sotiris Vimplis; Fredric Willmott
Journal: Anticancer Res Date: 2019-02 Impact factor: 2.480

Review 2. Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design.

Authors: Jonathan M L Ostrem; Kevan M Shokat
Journal: Nat Rev Drug Discov Date: 2016-07-29 Impact factor: 84.694

Review 3. A model for RAS mutation patterns in cancers: finding the sweet spot.

Authors: Siqi Li; Allan Balmain; Christopher M Counter
Journal: Nat Rev Cancer Date: 2018-12 Impact factor: 60.716

Review 4. Immunohistochemistry with Anti-BRAF V600E (VE1) Mouse Monoclonal Antibody is a Sensitive Method for Detection of the BRAF V600E Mutation in Colon Cancer: Evaluation of 120 Cases with and without KRAS Mutation and Literature Review.

Authors: Katerina Dvorak; Amanda Higgins; John Palting; Michael Cohen; Patrick Brunhoeber
Journal: Pathol Oncol Res Date: 2017-11-10 Impact factor: 3.201

4 in total

PROTAC-Mediated Degradation of KRAS Protein for Anticancer Therapeutics.

Review 1. The Role of KRAS in Endometrial Cancer: A Mini-Review.

Review 2. Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design.

Review 3. A model for RAS mutation patterns in cancers: finding the sweet spot.

Review 4. Immunohistochemistry with Anti-BRAF V600E (VE1) Mouse Monoclonal Antibody is a Sensitive Method for Detection of the BRAF V600E Mutation in Colon Cancer: Evaluation of 120 Cases with and without KRAS Mutation and Literature Review.

Review 1. PROTACs: great opportunities for academia and industry (an update from 2020 to 2021).

Review 2. Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants.

Review 3. Major Advances in Targeted Protein Degradation: PROTACs, LYTACs, and MADTACs.

Review 4. Recent Developments in Targeting RAS Downstream Effectors for RAS-Driven Cancer Therapy.